*Review* **The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas**

**Christina-Katharina Fodi 1,2, Jens Schittenhelm 2,3, Jürgen Honegger 1,2, Salvador Guillermo Castaneda-Vega 4,5,† and Felix Behling 1,2,\*,†**


**Abstract:** Meningiomas are the most common primary intracranial tumors. The majority of patients can be cured by surgery, or tumor growth can be stabilized by radiation. However, the management of recurrent and more aggressive tumors remains difficult because no established alternative treatment options exist. Therefore, innovative therapeutic approaches are needed. Studies have shown that meningiomas express somatostatin receptors. It is well known from treating neuroendocrine tumors that peptide radioreceptor therapy that targets somatostatin receptors can be effective. As yet, this therapy has been used for treating meningiomas only within individual curative trials. However, small case series and studies have demonstrated stabilization of the disease. Therefore, we see potential for optimizing this therapeutic option through the development of new substances and specific adaptations to the different meningioma subtypes. The current review provides an overview of this topic.

**Keywords:** meningioma; peptide receptor radionuclide therapy; PRRT; targeted therapy; somatostatin receptor; SSTR
